	Efectivo Y Equivalentes		Fecha
AbbVie	USD 5.23B	400M	2025-12
Acadia Pharmaceuticals	USD 819.69M	27.33M	2025-12
Akebia Therapeutics	USD 184.84M	18.4M	2025-12
ALKERMES	USD 388.57M	227.88M	2025-12
Alnylam Pharmaceuticals	USD 1.66B	167M	2025-12
Amarin	USD 122.8M	25.08M	2025-09
Amgen	USD 9.13B	316M	2025-12
Baxter International	USD 1.97B	240M	2025-12
Biogen	USD 3.01B	854.3M	2025-12
BioMarin Pharmaceutical	USD 1.31B	61.57M	2025-12
Bristol-Myers Squibb	USD 10.21B	5.52B	2025-12
Coherus Biosciences	USD 103.35M	113.54M	2025-09
Eli Lilly	USD 7.27B	2.52B	2025-12
Fujifilm	JPY 160.88B	906M	2025-09
Gilead Sciences	USD 7.33B	2.19B	2025-09
Ironwood Pharmaceuticals	USD 140.41M	47.56M	2025-09
Merck	USD 18.17B	10.16B	2025-09
Myriad Genetics	USD 145.4M	71M	2025-09
Pacira	USD 158.54M	10.96M	2025-12
Perrigo	USD 432.1M	22.1M	2025-09
Pfizer	USD 1.34B	295M	2025-09
PTC Therapeutics	USD 984.65M	312.03M	2025-12
Regeneron Pharmaceuticals	USD 18.87B	16.36B	2025-12
Sarepta Therapeutics	USD 801.28M	188.2M	2025-12
Teva Pharmaceutical Industries	USD 3.56B	1.35B	2025-12
Vertex Pharmaceuticals	USD 6.61B	321.1M	2025-12
Xencor	USD 54.07M	25.78M	2025-12
Zoetis	USD 2.08B	649M	2025-09

Coherus Biosciences Efectivo Y Equivalentes - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2026.